The Military HIV Research Program ( MHRP ) Clinical Trial Unit

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: Julie A. Ake
Organization: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
Fiscal Year: 2022
Award: $42,798
Funding agency: National Institute of Allergy and Infectious Diseases

Abstract
COVID-19 Vaccine Clinical Development Team
The USG enterprise to develop and optimize vaccine prevention modalities for SARS CoV-2 incorporates
the DAIDS HVTN as a key partner in strategic development, research prioritization and execution,
landscape analysis for future directions and analysis of outcomes. Dr. Robb has co-chaired and
participated in the USG Vaccine Development Team for clinical research along with the PI and others
within the HVTN. The administrative amendment to CTU funding to HJF will sustain Dr. Robb’s role in
this capacity.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Amendment><Armed Forces Personnel><CDC><COVID><COVID-19 vaccine><COVID-19 virus><COVID19 vaccine><COVID19 virus><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Clinical><Clinical Research><Clinical Study><Clinical Treatment Moab><Clinical Trials Network><Clinical Trials Unit><CoV disease><CoV-2><CoV2><Consultations><Development and Research><Elements><Funding><Future><Group Meetings><HIV><HIV Vaccine Trials Network><HVTN><Human Immunodeficiency Viruses><LAV-HTLV-III><Leadership><Lymphadenopathy-Associated Virus><Military><Military Personnel><Modality><Monoclonal Antibodies><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Outcome><Prevention><R & D><R&D><Research><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Testing><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States National Institutes of Health><V75><VTN><VTN gene><Vaccines><Virus-HIV><Vitronectin Gene><Wuhan coronavirus><clinical development><corona virus disease><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><develop a vaccine><develop vaccines><development of a vaccine><hCoV19><mAbs><meetings><military population><nCoV2><novel><pre-clinical><preclinical><programs><research and development><social role><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine antibodies><vaccine development><vaccine for novel coronavirus><vaccine induced antibodies><vaccine-induced antibodies>